%0 Journal Article %T A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC %A Christopoulos, Petros %A Thomas, Michael %J Journal of Thoracic Disease %D 2017 %B 2017 %9 %! A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC %K %X In the Lancet issue of last December Rittmeyer and colleagues reported the primary efficacy analysis of another landmark immunotherapy study (1): the randomized phase 3 OAK trial comparing atezolizumab (n=425), an anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, with docetaxel (n=425) for patients with squamous or adenocarcinomatous non-small cell lung cancer (NSCLC) progressing after one or more platinum-based combination regimens. %U https://jtd.amegroups.org/article/view/12412 %V 9 %N 3 %P E292-E294 %@ 2077-6624